Tadalafil Tablet, Film Coated
Product Images NDC 71335-1255

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71335-1255). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713351255)

This is a medication package containing Tadalafil 20mg tablets with the NDC number 7133512551. The tablets are yellow, oval, and marked with "20;S". The instructions mention storing the medication at room temperature between 20-25°C (68°-77°F) and keeping it out of reach of children. The package contains 30 tablets and has an expiration date listed as MM/YY, which is not visible in the text.*

FDA Label Image

Spl-tadalafil-figure-1 (Spl Tadalafil Figure 1)

This appears to be a table or chart showing measurements of blood pressure (systolic and diastolic) in different positions (standing and supine) before and after taking a medication (Tadalafil compared to a placebo). It also includes a time scale in hours. However, the formatting and readability are poor due to errors, so the information may not be entirely accurate.*

FDA Label Image

Spl-tadalafil-figure-2 (Spl Tadalafil Figure 2)

This is a chart displaying the standing and supine systolic blood pressure in mmHg at various times post-dose for individuals taking either tadalafil 20 mg and doxazosin 8 mg or placebo and doxazosin 8 mg.*

FDA Label Image

Spl-tadalafil-figure-3 (Spl Tadalafil Figure 3)

FDA Label Image

Spl-tadalafil-figure-4 (Spl Tadalafil Figure 4)

This is a graph showing plasma concentration of tadalafil at different doses and administration frequencies over time. The graph shows that a single 20mg dose produces a higher peak concentration compared to a single 5mg dose or daily 5mg dose given for 5 days. Tadalafil concentration decreases over time for all doses and administration frequencies.*

FDA Label Image

Spl-tadalafil-figure-5 (Spl Tadalafil Figure 5)

The text describes the change from baseline in IPSS total score and a comparison between Tadalafil 5mg and Placebo, with statistical significance marked by p<0.01. The duration of treatment in weeks is also mentioned.*

FDA Label Image

Spl-tadalafil-figure-6 (Spl Tadalafil Figure 6)

This data represents the change in IPSS total score between Tadalafil 5mg and a placebo over a treatment duration of 12 weeks. The graph shows a statistical significance (p<0.01) between the groups.*

FDA Label Image

Spl-tadalafil-figure-8 (Spl Tadalafil Figure 8)

This text presents the change from baseline in IPSS total score in a clinical trial. The information is compared between Tadalafil 5 mg and Placebo, showing a statistically significant difference with p<0.01. The duration of treatment in weeks is not specified.*

FDA Label Image

Spl-tadalafil-structure (Spl Tadalafil Structure)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.